Connect® MM- The Multiple Myeloma Disease Registry

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

Cohort 1 and 2

* Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
* Age ≥18 years
* Willing and able to provide signed informed consent
* Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Cohort 3

* Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
* Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
* Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

Exclusion Criteria:

Cohort 1 and 2

\- None

Cohort 3

* Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
* Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
* Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met.
* Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

• BACKGROUNDRifkin RM, Jagannath S, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Parikh K, Abouzaid S, Srinivasan S, Kitali A, Zafar F, Abonour R. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clin Ther. 2018 Jul;40(7):1193-1202.e1. doi: 10.1016/j.clinthera.2018.05.017. Epub 2018 Jul 23. PMID 30007443
• BACKGROUNDShah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17. PMID 28886839
• BACKGROUNDTerebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Jagannath S, Wagner L, Narang M, Flick ED, Srinivasan S, Yue L, Kitali A, Agarwal A, Rifkin RM; CONNECT MM Registry Investigators. Development of a prognostic model for overall survival in multiple myeloma using the Connect(R) MM Patient Registry. Br J Haematol. 2019 Dec;187(5):602-614. doi: 10.1111/bjh.16139. Epub 2019 Aug 5. PMID 31382320
• RESULTRifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, Srinivasan S, Ricafort R, Nagarwala Y, Durie BG. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):368-76. doi: 10.1016/j.clml.2014.12.002. Epub 2014 Dec 11. PMID 25617035
• RESULTRifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BG. Connect MM(R) - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13. No abstract available.